Trial Profile
Single-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3462817
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Dec 2019
Price :
$35
*
At a glance
- Drugs Peresolimab (Primary) ; Peresolimab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 20 Dec 2019 Status changed from active, no longer recruiting to completed.
- 16 Sep 2019 Planned End Date changed from 6 Nov 2019 to 12 Dec 2019.
- 16 Sep 2019 Planned primary completion date changed from 6 Nov 2019 to 12 Dec 2019.